Peanut allergy treatment shows promise in large study

NCT ID NCT04222491

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 500 people aged 6 months to 65 years with peanut allergy who are undergoing peanut oral immunotherapy. The goal is to see how many can tolerate a maintenance dose of 300 mg of peanut protein without symptoms within two years. Researchers also track changes in quality of life. The treatment involves eating small, increasing amounts of peanut flour to build tolerance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peanut flour (peanut allergen powder)
What this could lead to: If successful, this could show that oral immunotherapy helps many people with peanut allergy safely tolerate small amounts of peanut, reducing the risk of severe reactions from accidental exposure.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. Some participants may still have allergic reactions during treatment, and the maintenance dose is very small—not a cure or full tolerance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEANUT ALLERGY

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.